Abstract Details

Title Baseline cognitive function of patients with relapsing remitting multiple sclerosis is associated with therapeutic response to Natalizumab

Topic Multiple Sclerosis

Presentation(s) P6 - (-)

Poster/Presentation
Number 348

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Daniel Golan, MD (Carmel Medical Center) PRESENTER	No disclosure on file
Mark Gudesblatt, MD (South Shore Neurology Assoc. PC)	The institution of Dr. Gudesblatt has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for genentech. The institution of Dr. Gudesblatt has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen.
	No disclosure on file
Myassar Zarif	Myassar Zarif has nothing to disclose.
Barbara Bumstead, NP	Ms. Bumstead has nothing to disclose.
	No disclosure on file
Cynthia L. Sullivan, PhD (Neuropsychology Associates of Fairfax)	No disclosure on file
Jeffrey A. Wilken, PhD (NAF)	No disclosure on file
Karen Blitz-Shabbir, DO	No disclosure on file
Marijean Buhse (Stony Brook University)	Marijean Buhse has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
Glen M. Doniger, PhD (NeuroTrax Israel Ltd.)	No disclosure on file

��ɫ��